Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Appili TherapeuticsTSX:APLI EBITDA Margin % is 256.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Appili Therapeutics ranks worse than 78.83% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Appili Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was C$0.06 Mil. Appili Therapeutics's Revenue for the
three
months ended in Mar. 2026 was C$0.03 Mil. Therefore, Appili Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 256.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Appili Therapeutics EBITDA Margin % Related Terms
Appili Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Appili Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:APLI vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Appili Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Appili Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Appili Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Appili Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Appili Therapeutics (TSX:APLI) has a EBITDA Margin % of 256.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Appili Therapeutics and its competitors. According to the industry distribution chart, Appili Therapeutics ranks #741 out of 940 companies in the Biotechnology industry, placing it in the top 78.8%.
Is Appili Therapeutics' EBITDA Margin % too high?
Appili Therapeutics' current EBITDA Margin % is 256.00%. Based on the distribution chart, Appili Therapeutics ranks #741 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Appili Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Appili Therapeutics ranks #741 out of 940 companies for EBITDA Margin %. This places Appili Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Appili Therapeutics and its competitors. Appili Therapeutics's current EBITDA Margin % is 256.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (TSX:APLI) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.02, compared to a current price of C$0.01 — trading 50% below its estimated fair value. The current EBITDA Margin % is 256.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Appili Therapeutics (TSX:APLI), the current EBITDA Margin % is 256.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:APLI has been successfully added to your 
